Interleukin-2 (IL-2)-mediated Induction of the IL-2 Receptor alpha  Chain Gene
CRITICAL ROLE OF TWO FUNCTIONALLY REDUNDANT TYROSINE RESIDUES IN THE IL-2 RECEPTOR beta  CHAIN CYTOPLASMIC DOMAIN AND SUGGESTION THAT THESE RESIDUES MEDIATE MORE THAN STAT5 ACTIVATION*

(Received for publication, August 30, 1996, and in revised form, January 6, 1997)

Dana P. Ascherman Dagger , Thi-Sau Migone , Michael C. Friedmann and Warren J. Leonard §

From the Laboratory of Molecular Immunology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892-1674

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The interleukin-2 receptor alpha  chain (IL-2Ralpha ) is potently induced by antigens, mitogens, and certain cytokines that include IL-2 itself. This induction leads to the formation of high affinity IL-2 receptors when IL-2Ralpha is co-expressed with the beta  (IL-2Rbeta ) and gamma  (gamma c) chains of this receptor. We investigated the signaling pathways mediating IL-2-induced IL-2Ralpha mRNA expression using 32D myeloid progenitor cells stably transfected with either wild type IL-2Rbeta or mutants of IL-2Rbeta containing tyrosine to phenylalanine substitutions. Of the six cytoplasmic tyrosines in IL-2Rbeta , we have found that only the two tyrosines that mediate Stat5 activation (Tyr-392 and Tyr-510) contribute to IL-2-induced IL-2Ralpha gene expression and that either tyrosine alone is sufficient for this process. Interestingly, the IL-7 receptor contains a tyrosine (Tyr-429)-based sequence resembling the motifs encompassing Tyr-392 and Tyr-510 of IL-2Rbeta . Further paralleling the IL-2 system, IL-7 could activate Stat5 and drive expression of IL-2Ralpha mRNA in 32D cells transfected with the human IL-7R. However, IL-3 could not induce IL-2Ralpha mRNA in 32D cells, despite its ability to activate Stat5 via the endogenous IL-3 receptor. Moreover, the combination of IL-3 and IL-2 could not "rescue" IL-2Ralpha mRNA expression in cells containing an IL-2Rbeta mutant with phenylalanine substitutions at Tyr-392 and Tyr-510. These data suggest that Tyr-392 and Tyr-510 couple to an additional signaling pathway beyond STAT protein activation in IL-2-mediated induction of the IL-2Ralpha gene.


INTRODUCTION

Interleukin-2 (IL-2)1 is a pivotal cytokine that influences several arms of the immune system, including T cells, B cells, natural killer cells, and monocytes (1-4). Three classes of IL-2 receptors are known to exist: low affinity receptors contain the alpha  chain, intermediate affinity receptors contain the beta  and gamma  chains, and high affinity receptors contain all three chains (2-4). Interestingly, the beta  chain is also a component of the IL-15 receptor, whereas the gamma  chain is a common chain (gamma c) shared by the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (2-5). Mutations in gamma c form the genetic basis of X-linked severe combined immunodeficiency, a disease state affecting both cellular and humoral immunity (5, 6).

In lymphocytes, IL-2Rbeta and gamma c are constitutively expressed, while IL-2Ralpha is only expressed following activation by a variety of stimuli that include IL-2 itself (1, 7, 8). When induced, IL-2Ralpha complexes with beta  and gamma  chains to convert intermediate affinity to high affinity receptors (2-4). Although the intermediate and high affinity receptors are both functional (8-11), the induction of IL-2Ralpha is essential for normal immune function as evidenced by the autoimmunity, inflammatory bowel disease, and premature death occurring in IL-2Ralpha knockout mice (12). The regulation of IL-2Ralpha expression is tightly controlled at the level of transcription, relying on the interaction of positive regulatory elements with multiple transcription factors that include Stat5, Elf-1, HMG-I(Y), and NF-kappa B (Refs. 13 and 14 and references therein).

While many of the regulatory proteins and binding sequences influencing expression of the IL-2Ralpha gene have been defined, the more proximal events leading from IL-2 binding to IL-2Ralpha gene transcription are less clear. Previous work with the tyrosine kinase inhibitor herbimycin A has demonstrated the importance of tyrosine phosphorylation in IL-2-signaling (15). Among the proteins tyrosine-phosphorylated in response to IL-2 is IL-2Rbeta itself (16-19). This receptor chain contains six cytoplasmic tyrosines (Fig. 1), at least some of which can serve as phosphotyrosine docking sites for signaling proteins containing SH2 and PTB domains (20, 21).


Fig. 1. Schematic of human IL-2Rbeta , showing the positions of its six cytoplasmic tyrosines. All tyrosines but Tyr-361 are conserved in murine IL-2Rbeta . beta YYYYYY and beta FFFFFF indicate IL-2Rbeta constructs with tyrosines or phenylalanines, respectively, at Tyr-338, Tyr-355, Tyr-358, Tyr-361, Tyr-392, and Tyr-510; similar nomenclature was used for other IL-2Rbeta constructs.
[View Larger Version of this Image (12K GIF file)]


Examination of signaling via mutant IL-2Rbeta chains containing different tyrosine to phenylalanine substitutions therefore represents a method for mapping proximal events induced by IL-2 and has previously been used to investigate key functions such as proliferation (22-24). This analysis has demonstrated that tyrosine 338 (Tyr-338) mediates phosphorylation of the adaptor protein Shc (22, 25) (involved in ras activation), while Tyr-392 and Tyr-510 can independently direct activation of Stat5 (22-23, 26-28). To elucidate the role of these or other pathways in IL-2-induced expression of the IL-2Ralpha gene, we have examined multiple combinations of these tyrosine to phenylalanine substitutions in IL-2Rbeta . These experiments show that IL-2Rbeta mutants possessing Tyr-392 or Tyr-510 alone can augment expression of the IL-2Ralpha gene, whereas no IL-2Ralpha induction occurs when both Tyr-392 and Tyr-510 are mutated. Although previous studies link these tyrosines to Stat5 activation, our data suggest that Stat5 activation is not sufficient for IL-2Ralpha induction and that the same tyrosines may couple to additional signaling pathway(s).


MATERIALS AND METHODS

Reagents and Antibodies

Expression of IL-2Rbeta was assessed using a polyclonal antiserum to IL-2Rbeta (ErdA antiserum, Ref. 9) or 4G10 monoclonal antibody to phosphotyrosine (Upstate Biotechnology, Inc.).

Vectors and in Vitro Mutagenesis

Human IL-2Rbeta was mutated using the altered sites in vitro mutagenesis system (Promega) and oligonucleotides designed to change tyrosine (TAC) to phenylalanine (TTC), as described previously (22). Following sequence confirmation (Sequenase, U. S. Biochemical Corp.), mutant constructs were subcloned into the vector pME18S in which expression is driven by the SRalpha promoter (29). The human IL-7R cDNA has been described (30).

Cell Culture and Transfections

32D cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10-5 M 2-mercaptoethanol, 5% WEHI-3B conditioned medium (WEHI-CM) as a source of IL-3, 2 mM glutamine, and 100 units/ml each of penicillin and streptomycin. The transfectants expressing wild type and most of the mutant IL-2Rbeta constructs were described previously (22). Additional transfectants were generated by electroporating cells (5 × 106 cells/400 µl) with linearized plasmids consisting of IL-2Rbeta constructs and pCDNA3neo (InVitrogen) using a gene pulser (Bio-Rad; 300 V, 960 microfarads; time constants were approximately 30 ms). After 24 h, cells were aliquoted into 24-well plates and selected in 1 mg/ml G418 (Life Technologies, Inc.) for 2-3 weeks. Resistant clones were analyzed for IL-2Rbeta expression by flow cytometry with fluorescein isothiocyanate-conjugated anti-IL-2Rbeta monoclonal antibody (Endogen) or a control IgG2a (Becton Dickinson) on a FACSort FST (Becton Dickinson). In some cases, Western blotting with ErdA antiserum to IL-2Rbeta was used to further evaluate receptor expression. IL-7R transfectants were established in a similar fashion.

Cytokine Induction, RNA Preparation, and Northern Blot Analysis

32D transfectants grown to a density of 2-6 × 105 cells/ml were washed three times in acidified RPMI to strip any growth factors bound to the cell surface. Cells were then incubated for 16-18 h in medium containing either IL-3 (5% WEHI-CM), IL-2 (2 nM), IL-2 plus IL-3, or IL-7 (5 nM) plus IL-3, and RNA was prepared using TRIzol reagent (Life Technologies, Inc.) according to the established protocol. 30 µg of total RNA from each sample were run overnight in a 1% agarose formaldehyde gel and transferred to nylon membranes (Amersham Hybond). Equivalent loading and transfer of RNA was confirmed by ethidium bromide staining of the membrane. A 1.2-kilobase pair murine IL-2Ralpha cDNA fragment (31) was labeled with Life Technologies, Inc.'s random primer labeling kit and used to probe the blots. As an additional control for loading and expression of RNA, blots were also hybridized with a 1-kilobase pair murine glyceraldehyde-3-phosphate dehydrogenase cDNA fragment. All hybridizations were carried out for 20 h at 43 °C. Following multiple washes in SDS/SSPE-based solutions, blots were autoradiographed for 48-72 h at -70 °C.

Electrophoretic Mobility Shift Assays (EMSAs) and DNA Affinity Purification

EMSAs were performed as described previously (22). Wild type or transfected 32D cells (~5 × 105/ml) were washed and then depleted of growth factor for 4 h in phosphate-buffered saline or RPMI 1640 medium lacking serum and cytokines. Cells were then incubated at 37 °C for 20-30 min in RPMI, 10% fetal bovine serum medium with or without cytokines (2 nM IL-2, 5 nM IL-7, or 5% WEHI-CM). Following one wash in ice-cold phosphate-buffered saline, cells were lysed with three freeze thaw cycles to generate total cell extracts. Alternatively, nuclear extracts were prepared by standard methods. In EMSAs, 10 µg of total cell extract or 7 µg of nuclear extract were preincubated with 1 µg of poly(dI-dC) for 25 min and then combined with 20,000 cpm of a double-stranded 32P-labeled oligonucleotide probe corresponding to the gamma -interferon-activated site (GAS) of the Fcgamma RI gene (22) or the upstream (-1375 to -1334) GAS motif region of the murine IL-2Ralpha IL-2-response element (5'-GTGCAGTTTCGTACCAGACATGAG-3'; canonical and noncanonical GAS sites are underlined) (32). After an additional 20-min incubation on ice, samples were electrophoresed on a 5% polyacrylamide gel (0.5 × TBE (0.045 M Tris borate, 0.001 M EDTA)) and autoradiographed. Where indicated, polyclonal anti-Stat5 (26) or anti-Stat3 (gift of S. Chen-King) antiserum was added for antibody supershifting experiments. In the case of anti-Stat3, the binding reaction was performed prior to addition of antibody, and all reactions were carried out at room temperature. DNA affinity purification of Stat5a and Stat5b was performed using 400 µg of total cell extract and a biotinylated oligonucleotide containing a trimer of the beta -casein GAS motif, as described previously (33).


RESULTS

IL-2Rbeta Tyr-392 or Tyr-510 Is Required for IL-2-induced IL-2Ralpha mRNA Expression

32D cells lack IL-2Rbeta and are IL-3-dependent, but they can proliferate in response to IL-2 after IL-2Rbeta is transfected and expressed (22, 34). To assess the potential contribution of different IL-2Rbeta tyrosines in the signaling pathway(s) for IL-2-mediated IL-2Ralpha mRNA induction, we therefore examined 32D cells transfected with wild type or mutated forms of IL-2Rbeta . As shown previously (34), IL-3 could not mediate IL-2Ralpha gene expression in 32D cells transfected with wild type IL-2Rbeta , while IL-2 could induce IL-2Ralpha mRNA in the same cell line (Fig. 2A, lanes 3-4). The Northern blot analysis presented in Fig. 2A further demonstrated that IL-2 could potently induce IL-2Ralpha mRNA in all transfectants expressing IL-2Rbeta chains retaining the terminal two tyrosines (Tyr-392, Tyr-510) (lanes 4, 8, and 10). Simultaneous mutation of Tyr-392 and Tyr-510 completely blocked the induction of IL-2Ralpha mRNA (compare beta YYYYYY and beta YYYYFF, lanes 3-4 versus 11-12), indicating that at least one of these tyrosines is required for IL-2-mediated IL-2Ralpha gene expression. Further analysis revealed that either Tyr-392 or Tyr-510 alone is sufficient for this process (Fig. 2B), analogous to the functional overlap of Tyr-392 and Tyr-510 in mediating IL-2-induced proliferation (22). Of note, the fact that either of these tyrosines can mediate IL-2Ralpha gene expression, but Tyr-338 cannot, indicates that IL-2Ralpha induction is not absolutely required for proliferation (which can occur at suboptimal levels with Tyr-338 alone (22)) and further supports observations that pathways linked to Tyr-338 are not functionally equivalent to signals directed from Tyr-392 and Tyr-510 (22).


Fig. 2. Either Tyr-392 or Tyr-510 is sufficient for induction of IL-2Ralpha mRNA in 32D cells transfected with IL-2Rbeta constructs. A, Northern blot of 32D cells transfected with the indicated constructs. Cells were washed in acidified RPMI 1640 to strip the cell surface of growth factors and subsequently treated with 5% WEHI-CM (as a source of IL-3) or 2 nM IL-2 for 16-18 h. At least two high expressing IL-2Rbeta clones were assayed for each construct. Although some differences in the expression of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) control were observed, the degree of variation is not sufficient to explain the differences in IL-2Ralpha mRNA levels. B, Northern blot of 32D cells transfected with either beta FFFFFF (lanes 1, 2, 5, 6), beta FFFFYF (lanes 3 and 4) or beta FFFFFY (lanes 7 and 8) and stimulated as above. The existence of multiple murine IL-2Ralpha transcripts is consistent with previously published results (31, 34).
[View Larger Version of this Image (45K GIF file)]


Consistent with the functional redundancy of Tyr-392 and Tyr-510, previous work has shown that both Tyr-392 and Tyr-510 can independently mediate IL-2-induced Stat5 activation in 32D cells transfected with appropriate IL-2Rbeta constructs (22). Since each of these tyrosines shares a motif similar to that surrounding Tyr-429 of the IL-7 receptor (26) (Fig. 3A), we speculated that IL-7 could trigger IL-2Ralpha gene expression in 32D cells transfected with the IL-7 receptor. This hypothesis seemed plausible given the expression of IL-2Ralpha in double negative thymocytes normally exposed to IL-7 in vivo. Indeed, IL-7 induced both Stat5 activation (Fig. 3B) and IL-2Ralpha mRNA expression (Fig. 3C) in 32D-IL-7R transfectants.


Fig. 3. IL-7 also induces IL-2Ralpha mRNA in 32D cells transfected with the human IL-7R. A, similar motifs span IL-2Rbeta Tyr-392, IL-2Rbeta Tyr-510, and IL-7R Tyr-429, as reported previously (22). B, IL-7 induces STAT protein binding to the Fcgamma RI probe in 32D cells transfected with the human IL-7R. Parental 32D cells or 32D-IL-7R transfectants were deprived of growth factors for 4 h and then incubated for 30 min with 0 or 5 nM IL-7. Nuclear extracts were prepared and EMSAs performed as described. Anti-Stat5 antiserum (lane 5) supershifted (asterisk) the IL-7-induced complex (arrowhead), whereas an anti-Stat3 antiserum capable of supershifting murine Stat3 (39) did not (lane 6). C, IL-7 induces IL-2Ralpha mRNA in 32D cells transfected with the human IL-7R. Parental 32D cells (lanes 1 and 2) or 32D-IL-7R transfectants (lanes 3 and 4) were washed with acidified RPMI 1640 and stimulated with IL-3 (5% WEHI-CM, lanes 1 and 3) or IL-3 plus 5 nM IL-7 (lanes 2 and 4) for 16 h. Northern blot analysis was performed as described under "Materials and Methods." G3PDH, glyceraldehyde-3-phosphate dehydrogenase.
[View Larger Version of this Image (41K GIF file)]


Stat5 Induction Alone Is Not Sufficient to Induce IL-2Ralpha mRNA in 32D Cells

Collectively, these results suggested an important role for Stat5 activation in the induction of IL-2Ralpha mRNA. Hence, the inability of IL-3 (which also can activate Stat5 (35, 36)) to augment expression of IL-2Ralpha mRNA (Fig. 2A) was surprising, particularly since IL-2 and IL-3 induced indistinguishable STAT complexes in IL-2Rbeta -transfected 32D cells when performing EMSAs with a probe comprised of the murine IL-2Ralpha GAS motifs. As shown in Fig. 4, the complexes resulting from IL-2 or IL-3 treatment (lanes 2 and 3) supershifted with anti-Stat5 antiserum (lanes 5 and 6), but not with anti-Stat3 (lanes 8 and 9). Similar results were obtained using the Fcgamma RI GAS site as a probe (data not shown). Because the anti-Stat5 antiserum used in these experiments recognizes two closely related proteins termed Stat5a and Stat5b, we performed additional supershift experiments with Stat5a- and Stat5b-specific antisera to exclude the possibility that IL-2 and IL-3 differed in their induction of these proteins. In fact, this analysis demonstrated that both cytokines could independently activate Stat5a and Stat5b in 32D cells transfected with wild type IL-2Rbeta (Fig. 5A). DNA affinity purification of STAT proteins with an oligonucleotide probe containing a trimer of the beta -casein GAS motif confirmed these results (Fig. 5B). Overall, these data indicate that Stat3 is not required for IL-2-induced IL-2Ralpha expression in 32D cells and that Stat5a/Stat5b activation alone is not sufficient to mediate IL-2Ralpha mRNA induction, supporting a role for additional cooperating signal(s). Of note, the fact that IL-2 and IL-3 (which normally exert effects on different cell types) differ in their capacity to induce IL-2Ralpha gene expression within the same cell line indicates that such cooperating signals depend on the receptor system rather than cell lineage alone.


Fig. 4. Stat5 is induced by both IL-2 and IL-3 in 32D-IL-2Rbeta transfectants. EMSAs of 32D transfectants stimulated with WEHI-CM (as a source of IL-3, lanes 2, 5, and 8) or 2 nM IL-2 (lanes 3, 6, and 9) were performed as described under "Materials and Methods" using a 42-base pair probe corresponding to the GAS sites of the murine IL-2Ralpha IL-2-response element. Where indicated, the resulting complexes were subjected to supershifting with antibodies directed against Stat5 (lanes 4-6) or Stat3 (lanes 7-9). The arrowhead indicates the inducible STAT complex, while the asterisk shows the location of the anti-Stat5 supershifted band.
[View Larger Version of this Image (71K GIF file)]



Fig. 5. IL-2 and IL-3 independently activate both Stat5a and Stat5b in 32D-IL-2Rbeta transfectants. A, supershift analysis performed using the murine IL-2Ralpha IL-2-response element probe described in Fig. 4 with antiserum directed against Stat5a (lanes 4-6) or Stat5b (lanes 7-9). Arrowhead, unshifted complex; asterisk, shifted complexes. B, DNA affinity purification and Western blotting of total cell lysates prepared from 32D-IL-2Rbeta transfectants treated for 20 min with no cytokine (lanes 1 and 4), 2 nM IL-2 (lanes 2 and 5), or 5% WEHI (lanes 3 and 6). A biotinylated oligonucleotide containing a trimer of the beta -casein GAS motif was used for affinity purification in this experiment. Eluted proteins were blotted with antiserum against Stat5a (lanes 1-3) or Stat5b (lanes 4-6).
[View Larger Version of this Image (30K GIF file)]


IL-3 Is Unable to Rescue IL-2Ralpha Gene Induction in 32D-beta YYYYFF Cells

Given the possibility that IL-2Ralpha gene expression requires the coupling of Stat5 activation with other IL-2-derived signals, we examined the ability of IL-3 to complement IL-2 and rescue expression of the IL-2Ralpha gene in 32D cells transfected with beta YYYYFF. Surprisingly, however, the combination of IL-2 and IL-3 did not induce IL-2Ralpha mRNA in cells transfected with beta YYYYFF (Fig. 6A, lanes 3-5), despite the activation of STAT complexes indistinguishable from those induced by IL-2 in cells containing beta YYYYYY (Fig. 6B, lanes 4-6 versus 9-11). This experiment demonstrates that the four proximal tyrosines as well as the nonphosphorylated regions of IL-2Rbeta cannot provide signals sufficient to cooperate with IL-3-mediated Stat5 activation in directing expression of IL-2Ralpha mRNA. These data therefore suggest that the additional factor(s) involved in IL-2-mediated IL-2Ralpha gene induction may also be linked functionally to Tyr-392 and Tyr-510.


Fig. 6. Failure of IL-2 plus IL-3 to induce IL-2Ralpha mRNA in 32D-beta YYYYFF cells (A), even though Stat5 is activated in these cells (B). A, Northern blot analysis performed on 32D-beta YYYYFF transfectants treated with IL-3 (5% WEHI-CM, lane 3), 2 nM IL-2 (lane 4), or IL-2 plus IL-3 (lane 5). Included for comparison is RNA isolated from 32D-IL-2Rbeta (wild type) transfectants treated with IL-3 (lane 1) or 2 nM IL-2 (lane 2). The minor IL-2Ralpha band in IL-3-treated 32D-IL-2Rbeta transfectants was occasionally observed in some of the wild type or mutant IL-2Rbeta transfected cell lines. G3PDH, glyceraldehyde-3-phosphate dehydrogenase. B, EMSA performed using the murine IL-2Ralpha IL-2-response element probe of Fig. 4 on total cell lysates from 32D-beta YYYYFF (lanes 1-6) and 32D-beta YYYYYY (lanes 7-11) transfectants stimulated for 15-20 min without cytokine (lanes 1 and 7), with IL-3 (5% WEHI-CM, lanes 2 and 8), with IL-2 (2 nM, lanes 3 and 9), or with IL-2 plus IL-3 (lane 4). Supershifting antibodies directed against Stat5 (lanes 5 and 10) or Stat3 (lanes 6 and 11) were added to further characterize the resulting DNA·protein complexes. Arrowhead, unshifted complex; asterisk, anti-Stat5 supershifted complex.
[View Larger Version of this Image (37K GIF file)]



DISCUSSION

Using IL-2Rbeta constructs containing various combinations of tyrosine to phenylalanine substitutions, we have demonstrated that in the context of full-length IL-2Rbeta either Tyr-392 or Tyr-510 is sufficient to direct IL-2-mediated induction of the IL-2Ralpha gene. Based on these results, at least four different models potentially explain the proximal events in IL-2Ralpha gene induction following binding of IL-2 to its receptor. In the first model, STATs are activated after docking at phosphorylated Tyr-392 or Tyr-510 and by themselves are sufficient for IL-2Ralpha gene induction (Fig. 7A). However, the failure of IL-3 to promote IL-2Ralpha gene expression in 32D transfectants minimizes this possibility, as the same STAT proteins are activated by IL-2 and IL-3 (Figs. 4 and 5).


Fig. 7. Models of IL-2-mediated IL-2Ralpha gene induction. A, this model couples STAT activation to Tyr-392 or Tyr-510 and attributes IL-2Ralpha gene induction to STAT activation alone. B, this scheme links Tyr-392 or Tyr-510 to activation of an unknown factor X that is sufficient to drive expression of the IL-2Ralpha gene. The remaining two diagrams presented in C and D involve a combination of STAT activation and an unknown factor X. C, while STATs are activated via phosphorylated Tyr-392 or Tyr-510, factor X interacts in cis from a distinct portion of IL-2Rbeta . D, the final model depicts the activation of both STATs and factor X from Tyr-392 or Tyr-510.
[View Larger Version of this Image (26K GIF file)]


The remaining models therefore assume that STAT protein activation is not the sole pathway triggered by IL-2 in the induction of IL-2Ralpha mRNA. For example, the second model (Fig. 7B) portrays a direct interaction between an undefined "X" factor and Tyr-392 or Tyr-510, without the need for concomitant STAT activation. However, this paradigm is unlikely given the existence of consensus STAT binding sequences in the upstream region of the human and murine IL-2Ralpha promoters and the inability of IL-2 to induce IL-2Ralpha promoter activity when these binding sequences are mutated (14, 32). Incorporating these facts, the third model (Fig. 7C) depicts the interaction of STAT proteins activated at Tyr-392 or Tyr-510 with an unknown factor X bound to a different portion of IL-2Rbeta . In this scheme, the requirement for these signaling molecules to functionally collaborate in cis accounts for the inability of IL-3 to rescue IL-2Ralpha gene induction when providing activated STATs in trans. Finally, the fourth model (Fig. 7D) links Tyr-392 and Tyr-510 to the activation of both STAT proteins and an additional signaling molecule (factor X). This scheme effectively couples both Tyr-392 and Tyr-510 to two separate pathways that cooperate in IL-2Ralpha gene induction. In turn, the "non-STAT" pathway may influence activation of other transcription factors required for IL-2Ralpha mRNA expression, consistent with the complex regulation of this gene (13, 14, 32).

Although we favor the final model, the identity of the putative additional signaling molecule for IL-2-induced IL-2Ralpha gene expression is unknown. Examination of the IL-7 receptor system may provide some insights in view of its functional overlap with IL-2Rbeta . For example, in addition to Stat5 activation (26), Tyr-429 of the IL-7R has been implicated in the activation of PI 3-kinase (37). Along these lines, one published report proposed a direct interaction between Tyr-392 of IL-2Rbeta and PI 3-kinase based on phosphopeptide competition experiments (38). Yet, because the same analysis failed to demonstrate any interaction between PI 3-kinase and Tyr-510 of IL-2Rbeta (38), PI 3-kinase is unlikely to represent the missing molecule depicted in Fig. 7D that must be capable of interacting with Tyr-510 as well as Tyr-392. Further comparison of the IL-7 and IL-2 receptor systems reveals that both receptors employ Jak1 and Jak3. In contrast, IL-3 signaling involves Jak2. However, the use of Jak2 instead of Jak1 and Jak3 does not fully explain the inability of IL-3 to induce the IL-2Ralpha gene, as erythropoietin also activates Jak2 but can induce IL-2Ralpha mRNA in 32D cells transfected with the murine erythropoietin receptor (data not shown).

In conclusion, we have demonstrated that Tyr-392 and Tyr-510 play vital but redundant roles in IL-2Ralpha gene induction. Although more work is required to clarify the proximal events that culminate in IL-2-mediated expression of this gene, the evidence supports the existence of additional signaling molecule(s)/pathway(s) linked to Tyr-392 and Tyr-510. Defining the missing element(s) may reveal yet another IL-2-mediated signaling pathway and provide insight to critical processes regulating the immune response.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Supported in part by a Fellowship from the National Arthritis Foundation.
§   To whom correspondence should be addressed: NHLBI, Bldg. 10, Rm. 7N244, NIH, Bethesda, MD 20892-1674. Tel.: 301-496-0098; Fax: 301-402-0971; E-mail: wjl{at}helix.nih.gov.
1   The abbreviations used are: IL, interleukin; EMSA, electrophoretic mobility shift assay; GAS, gamma -interferon-activated site; PI 3-kinase, phosphatidylinositol 3-kinase.

ACKNOWLEDGEMENTS

We thank Cetus Corp. as well as G. Ju and J. Hakimi, Hoffmann La Roche for recombinant IL-2; S. Chen-King for anti-Stat3 antiserum; A. Miyajima for pME18S; S. Ziegler and Immunex Corp. for the human IL-7R cDNA; J.-X. Lin for Stat5, Stat5a, and Stat5b antisera, as well as the DNA affinity purification experiment; J. Pierce for 32D-EpoR transfectants; and S. John for critical comments.


REFERENCES

  1. Waldmann, T. A. (1989) Annu. Rev. Biochem. 58, 875-911 [CrossRef][Medline] [Order article via Infotrieve]
  2. Leonard, W. J., Noguchi, M., Russell, S. M., and McBride, O. W. (1994) Immunol. Rev. 138, 61-86 [Medline] [Order article via Infotrieve]
  3. Sugamura, K., Asao, H., Kondo, M., Tanaka, N., Ishii, N., Nakamura, M., and Takeshita, T. (1995) Adv. Immunol. 59, 225-277 [Medline] [Order article via Infotrieve]
  4. Taniguchi, T. (1995) Science 268, 251-255 [Medline] [Order article via Infotrieve]
  5. Leonard, W. J. (1996) Annu. Rev. Med. 47, 229-239 [CrossRef][Medline] [Order article via Infotrieve]
  6. Noguchi, M., Yi, H., Rosenblatt, H. M., Filipovich, A. H., Adelstein, S., Modi, W. S., McBride, O. W., and Leonard, W. J. (1993) Cell 73, 147-157 [Medline] [Order article via Infotrieve]
  7. Leonard, W. J., Depper, J. M., Robb, R. J., Waldmann, T. A., and Greene, W. C. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 6957-6961 [Abstract]
  8. Siegel, J. P., Sharon, M., Smith, P. L., and Leonard, W. J. (1987) Science 238, 75-78 [Medline] [Order article via Infotrieve]
  9. Nakamura, Y., Russell, S. M., Mess, S. A., Friedmann, M., Erdos, M., Francois, C., Jacques, Y., Adelstein, S., and Leonard, W. J. (1994) Nature 369, 330-333 [CrossRef][Medline] [Order article via Infotrieve]
  10. Nelson, B. H., Lord, J. D., and Greenberg, P. D. (1994) Nature 369, 333-336 [CrossRef][Medline] [Order article via Infotrieve]
  11. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., and Sugamura, K. (1992) Science 257, 379-382 [Medline] [Order article via Infotrieve]
  12. Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A., and Alt, F. W. (1995) Immunity 3, 521-530 [Medline] [Order article via Infotrieve]
  13. John, S., Reeves, R. B., Lin, J.-X., Child, R., Leiden, J. M., Thompson, C. B., and Leonard, W. J. (1995) Mol. Cell. Biol. 15, 1786-1796 [Abstract]
  14. John, S., Robbins, C. M., and Leonard, W. J. (1996) EMBO J. 15, 5627-5635 [Abstract]
  15. Otani, H., Erdos, M., and Leonard, W. J. (1993) J. Biol. Chem. 268, 22733-22736 [Abstract/Free Full Text]
  16. Sharon, M., Gnarra, J. R., and Leonard, W. J. (1989) J. Immunol. 143, 2530-2533 [Abstract/Free Full Text]
  17. Asao, H., Takeshita, T., Nakamura, M., Nagata, K., and Sugamura, K. (1990) J. Exp. Med. 171, 637-644 [Abstract]
  18. Mills, G. B., May, C., McGill, M., Fung, M., Baker, M., Sutherland, R., and Greene, W. C. (1990) J. Biol. Chem. 265, 3561-3567 [Abstract/Free Full Text]
  19. Shackelford, D. A., and Trowbridge, I. S. (1991) Cell Regul. 2, 73-85 [Medline] [Order article via Infotrieve]
  20. Heldin, C. H. (1995) Cell 80, 213-223 [Medline] [Order article via Infotrieve]
  21. van der Greer, P., and Pawson, T. (1995) Trends Biochem. Sci. 20, 277-280 [CrossRef][Medline] [Order article via Infotrieve]
  22. Friedmann, M. C., Migone, T.-S., Russell, S. M., and Leonard, W. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2077-2082 [Abstract/Free Full Text]
  23. Liu, K. D., Lai, S. Y., Goldsmith, M. A., and Greene, W. C. (1995) J. Biol. Chem. 270, 22176-22181 [Abstract/Free Full Text]
  24. Evans, G. A., Goldsmith, M. A., Johnston, J. A., Xu, W., Weiler, S. R., Erwin, R., Howard, O. M. Z., Abraham, R. T., O'Shea, J. J., Greene, W. C., and Farrar, W. L. (1995) J. Biol. Chem. 270, 28858-28863 [Abstract/Free Full Text]
  25. Ravichandran, K. S., Igras, V., Shoelson, S. E., Fesik, S. W., and Burakoff, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5275-5280 [Abstract/Free Full Text]
  26. Lin, J.-X., Migone, T.-S., Tsang, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., and Leonard, W. J. (1995) Immunity 2, 331-339 [Medline] [Order article via Infotrieve]
  27. Fujii, H., Nakagawa, Y., Schindler, U., Kawahara, A., Mori, H., Gouilleux, F., Groner, B., Ihle, J. N., Minami, Y., Miyazaki, T., and Taniguchi, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5482-5486 [Abstract]
  28. Gaffen, S. L., Lai, S. Y., Xu, W., Gouilleux, F., Groner, B., Goldsmith, M. A., and Greene, W. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7192-7196 [Abstract]
  29. Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., and Arai, N. (1988) Mol. Cell. Biol. 8, 466-472 [Medline] [Order article via Infotrieve]
  30. Goodwin, R. G., Friend, D., Ziegler, S. F., Jerzy, R., Falk, B. A., Gimpel, S., Cosman, D., Dower, S. K., March, C. J., Namen, A. E., and Park, L. S. (1990) Cell 60, 941-951 [Medline] [Order article via Infotrieve]
  31. Miller, J., Malek, T. R., Leonard, W. J., Greene, W. C., Shevach, E. M., and Germain, R. N. (1985) J. Immunol. 134, 4212-4217 [Abstract/Free Full Text]
  32. Sperisen, P., Wang, S. M., Soldaini, E., Pla, M., Rusterholz, C., Bucher, P., Corthesy, P., Reichenbach, P., and Nabholz, M. (1995) J. Biol. Chem. 270, 10743-10753 [Abstract/Free Full Text]
  33. Lin, J.-X., Mietz, J., Modi, W. S., John, S., and Leonard, W. J. (1996) J. Biol. Chem. 271, 10738-10744 [Abstract/Free Full Text]
  34. Otani, H., Siegel, J. P., Erdos, M., Gnarra, J. R., Toledano, M. B., Sharon, M., Mostowski, H., Feinberg, M. B., Pierce, J. H., and Leonard, W. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2789-2793 [Abstract]
  35. Mui, A., Wakao, H., O'Farrell, A. M., Harada, N., and Miyajima, A. (1995) EMBO J. 14, 1166-1175 [Abstract]
  36. Azam, M., Erdjument-Bromage, H., Kreider, B. L., Xia, M., Quelle, F., Basu, R., Saris, C., Tempst, P., Ihle, J. N., and Schindler, C. (1995) EMBO J. 14, 1402-1411 [Abstract]
  37. Venkitaraman, A. R., and Cowling, R. J. (1994) Eur. J. Immunol. 24, 2168-2174 [Medline] [Order article via Infotrieve]
  38. Truitt, K. E., Mills, G. B., Turck, C. W., and Imboden, J. B. (1994) J. Biol. Chem. 269, 5937-5943 [Abstract/Free Full Text]
  39. Hilbert, D. M., Migone, T. S., Kopf, M., Leonard, W. J., and Rudikoff, S. (1996) Immunity 5, 81-89 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.